{"doi":"10.1517/14656566.6.7.1127","title":"Current treatment options for myeloma","abstract":null,"journal":"Expert Opinion on Pharmacotherapy","year":2005,"id":620929,"datarank":0.38474240361923057,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"self_citation_contribution":0.38474240361923057,"citation_network_contribution":0.0,"self_endowment_contribution":0.38474240361923057,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":12,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1603097,"name":"Amin Rahemtulla","orcid":null,"position":1,"is_corresponding":false},{"id":1603098,"name":"Meletios-Athanassios Dimopoulos","orcid":null,"position":2,"is_corresponding":false},{"id":336801,"name":"Evangelos Terpos","orcid":"0000-0001-5133-1422","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Current treatment options for myeloma","abstract":"In most cases multiple myeloma is an incurable plasma cell malignancy. Despite the use of conventional therapy or high-dose chemotherapy with autologous stem cell transplantation (ASCT), patients continue to relapse at a constant rate. A small minority of patients are cured by allogeneic transplantation. Novel drugs targeting not only the myeloma cell but also its interactions with the malignant microenvironment have recently been used in patients with relapsed/refractory disease. So far, ASCT has been the treatment of choice for eligible myeloma patients. However, many questions regarding the management of myeloma patients remain unanswered. How safe is ASCT in elderly patients? Is there a role for non-myeloablative allogeneic transplantation in multiple myeloma? What is the role of novel agents, such as thalidomide, its analogues and bortezomib, in the treatment of newly diagnosed patients or as maintenance post-ASCT? This review summarises all available data for the current treatment options for myeloma providing a useful algorithm for its management.","is_dataset_classified":null,"base_score":2.5649493574615367,"endowment":2.5649493574615367,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"15957967","pmcid":null,"openalex_id":"https://openalex.org/W1994903901","authors":[],"funders":[],"total_grants":0,"fwci":0.8561,"citation_percentile":0.71316276,"influential_citations":0,"citation_trend":[{"year":2017,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.1517/14656566.6.7.1127","host_type":"publisher"},{"url":"https://doi.org/10.1517/14656566.6.7.1127","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15957967","host_type":"repository"}],"fields_of_study":["Multiple Myeloma Research and Treatments","Protein Degradation and Inhibitors","Ubiquitin and proteasome pathways","Age Factors","Algorithms","Antineoplastic Agents","Antineoplastic Combined Chemotherapy Protocols","Bone Density Conservation Agents","Boronic Acids","Bortezomib","Combined Modality Therapy","Diphosphonates","Doxorubicin","Humans","Melphalan","Multiple Myeloma","Osteolysis","Prednisolone","Pyrazines","Randomized Controlled Trials as Topic","Recurrence","Stem Cell Transplantation","Survival Analysis","Thalidomide","Transplantation, Autologous","Vincristine"],"mesh_terms":["Bortezomib","Age Factors","Algorithms","Antineoplastic Agents","Antineoplastic Combined Chemotherapy Protocols","Boronic Acids","Combined Modality Therapy","Diphosphonates","Doxorubicin","Humans","Melphalan","Multiple Myeloma","Osteolysis","Prednisolone","Pyrazines","Recurrence","Thalidomide","Transplantation, Autologous","Vincristine","Survival Analysis","Randomized Controlled Trials as Topic","Stem Cell Transplantation","Bone Density Conservation Agents"],"keywords":["Medicine","Multiple myeloma","Bortezomib","Thalidomide","Autologous stem-cell transplantation","Lenalidomide","Oncology","Internal medicine","Malignancy","Transplantation","Chemotherapy","Disease","Intensive care medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T12:36:36.704917Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}